Kennedy Vaccine Remarks Raise Stakes for Overton Confirmation Hearing
The stakes surrounding Heidi Overton’s nomination to lead FDA grew considerably this week as HHS secretary Robert F. Kennedy Jr. publicly renewed his alignment with the vaccine-skeptic movement, putting the prospective FDA commissioner squarely in the middle of the Trump administration’s increasingly contentious vaccine policies.
Kennedy on Thursday delivered the keynote address at a conference of Children’s Health Defense, the organization he previously chaired, telling attendees concerned about vaccines that they have a “strong and steadfast friend at the White House.” Kennedy also indicated that he had wanted to make more sweeping changes upon taking office but had been constrained by government procedures and legal requirements.
The appearance was notable because Kennedy had distanced himself from Children’s Health Defense during his confirmation process. Since becoming HHS secretary, however, he has pursued significant changes to federal vaccine policy and oversight, while maintaining that the administration is seeking better evidence on vaccine safety and strengthening public confidence through what HHS calls “gold-standard” research.
That backdrop is likely to sharpen scrutiny of Overton when she appears before the Senate Health, Education, Labor and Pensions Committee 9/24 for her FDA commissioner confirmation hearing (see earlier story).
FDA occupies a particularly consequential position in the vaccine debate. While CDC recommendations guide how vaccines are used, FDA determines whether vaccines can be marketed based on assessments of safety, effectiveness and manufacturing quality.
Overton already has been drawn into the controversy. She appeared with President Trump when he announced an executive order seeking changes to the childhood vaccination schedule. Senate HELP Committee chairman Bill Cassidy (R-LA), a physician who has challenged several of the administration’s vaccine initiatives, subsequently called Overton’s involvement in the rollout “almost disqualifying.”
The confirmation hearing therefore could provide senators their first extended opportunity to determine how Overton views FDA’s scientific independence on vaccines and how she would respond if the agency’s scientific assessments conflict with vaccine policies favored by Kennedy or the White House.
The developments also represent a change from the administration’s posture earlier this year. The Washington Post reported in June that Republican strategists had concluded vaccine skepticism presented political risks ahead of the November midterm elections and that HHS officials understood a major change to childhood vaccine recommendations earlier in the year was expected to be the administration’s last high-profile vaccine initiative for some time. Vaccine-related work nevertheless continued largely outside public view.
More recently, that lower-profile approach has given way to renewed public activity. The administration has again pushed changes involving childhood vaccinations, and Kennedy’s appearance before Children’s Health Defense represents perhaps the clearest indication that he is willing to publicly embrace the issue despite its political sensitivity.
For FDA, the timing is particularly significant. The agency remains without a Senate-confirmed commissioner as consequential questions about vaccine regulation continue to move through HHS and the White House.
Overton’s hearing may therefore be about considerably more than her qualifications to manage FDA. It could also clarify where the prospective commissioner believes FDA’s regulatory authority and scientific judgment begin, and where policy priorities of Kennedy and the White House end.